VMD Viemed Healthcare (VMD) Insider Trading, Ownership & Congress Trades
Healthcare Services · Services-misc health & allied services, nec · CIK 0001729149
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
98
13F, latest reported quarter
Conversions, 180 days
8
Codes C/M, not in net · $18.1K priced
What the filings say about VMD
Insiders, 180 days
-$347.2K net sold
2 sellers · 0% of sales under a 10b5-1 plan
Viemed Healthcare insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, VIEMED HEALTHCARE, INC. insiders sold a net $347.2K of stock across 37 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 13.7% of the 73,214 shares held after it.
- 1 other insider sold within 30 days.
- 98 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Medical Officer Frazier William sold about $117.2K of VMD on Jun 25, 2026; 1 other insider sold within 30 days and 98 funds added in the latest 13F quarter.Context
- 8 earlier Form 4 trades (code P or S) here by this insider (8 sales), the last on Mar 14, 2025.
- The trade is 3.7% of the 90,518 shares held after it.
- 1 other insider sold within 30 days.
- 98 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Smokoff Timothy sold about $38.7K of VMD on Jun 24, 2026; 1 other insider sold within 30 days and 98 funds added in the latest 13F quarter.Context
- 8 earlier Form 4 trades (code P or S) here by this insider (8 sales), the last on Mar 14, 2025.
- The trade is 5.8% of the 85,518 shares held after it.
- 1 other insider sold within 30 days.
- 98 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Smokoff Timothy sold about $57.8K of VMD on Jun 24, 2026; 1 other insider sold within 30 days and 98 funds added in the latest 13F quarter.Context
- 8 earlier Form 4 trades (code P or S) here by this insider (8 sales), the last on Mar 14, 2025.
- The trade is 6.6% of the 75,518 shares held after it.
- 1 other insider sold within 30 days.
- 98 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Smokoff Timothy sold about $57.0K of VMD on Jun 24, 2026; 1 other insider sold within 30 days and 98 funds added in the latest 13F quarter.Context
- 8 earlier Form 4 trades (code P or S) here by this insider (8 sales), the last on Mar 14, 2025.
- The trade is 1.7% of the 93,882 shares held after it.
- 1 other insider sold within 30 days.
- 98 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Smokoff Timothy sold about $18.8K of VMD on Jun 24, 2026; 1 other insider sold within 30 days and 98 funds added in the latest 13F quarter.37 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net -$347.2K over 180 days
more than 63% of Healthcare Services
Congress
no House purchase disclosed in the last 12 months
Funds
98 funds bought in last quarter
below 65% of Healthcare Services
Revenue
+20.5% year over year
more than 70% of Healthcare Services
Margin
5.5% net margin
more than 71% of Healthcare Services
Buybacks
$6.8M repurchased, FY to 2026-06-30
below 87% of Healthcare Services
Short interest
5.1% of the float short (float per yahoo 2026-10-26) · 5.7 days to cover · settled 2026-09-30
more than 56% of Healthcare Services
What changed in the last 30 days
Oct 28Insider selling stopped: no sales in 90 days after 6 in the prior 90
Why it matters
The absence is the signal: 6 sales in one 90-day window and none in the next is a change of behaviour, not a filing.
Watch VMD
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+41.7%12M
Insider sell
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns VMD: institutional holders (13F)
13F holdings, latest reported quarter
4,788,307 sh
$54.6M
2,141,184 sh
$24.4M
1,321,676 sh
$15.1M
1,264,890 sh
$14.4M
1,222,534 sh
$13.9M
Congress trades in VMD
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
VMD planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
VMD mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Columbia Integrated Small Cap Growth Fund
$391.4K position · as of 2026-05-31
1.2%
North Star Micro Cap Fund
$984.0K position · as of 2026-05-31
0.5%
First Trust Dow Jones Select MicroCap Index Fund
$1.3M position · as of 2026-06-30
0.5%
NVIT GS Small Cap Equity Insights Fund
$736.8K position · as of 2026-06-30
0.3%
Hartford Multifactor Small Cap ETF
$197.4K position · as of 2026-07-31
0.3%
Ultra-Small Company Fund
$289.5K position · as of 2026-06-30
0.3%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Executive pay vs shareholder return · Casey Hoyt
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$2.6M
$2.3M
$2.0M
+42%
+0%
2024
$2.6M
$2.5M
$1.5M
+54%
-15%
2023
$2.5M
$2.5M
$1.4M
+50%
-16%
2022
$1.9M
$2.8M
$1.1M
+45%
-20%
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows a net $347.2K sold by insiders over 180 days, 98 funds added last quarter. Each figure is a federal filing, dated the day it went public.
VMD financials
Revenue growth
+20.5%
XBRL, annual
Net margin
5.5%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$301.6M
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM VMD
| FY Dec 2025 | $270.3M |
| FY Dec 2024 | $224.3M |
| FY Dec 2023 | $183.0M |
| FY Dec 2022 | $138.8M |
| FY Dec 2021 | $117.1M |
| Jun 2026 | $78.1M |
| Mar 2026 | $75.4M |
| Dec 2025 | $76.2M |
| Sep 2025 | $71.9M |
| Jun 2025 | $63.1M |
| Mar 2025 | $59.1M |
| Dec 2024 | $60.7M |
| Sep 2024 | $58.0M |
At each fiscal year end
Single quarter
Net margin, TTM
+5.0%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM VMD
| FY Dec 2025 | +5.7% |
| FY Dec 2024 | +5.1% |
| FY Dec 2023 | +5.6% |
| FY Dec 2022 | +4.5% |
| FY Dec 2021 | +7.8% |
| Jun 2026 | +3.5% |
| Mar 2026 | +3.4% |
| Dec 2025 | +8.0% |
| Sep 2025 | +4.9% |
| Jun 2025 | +5.0% |
| Mar 2025 | +4.4% |
| Dec 2024 | +7.3% |
| Sep 2024 | +6.7% |
At each fiscal year end
Single quarter
Free cash flow, TTM
$29.2M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM VMD
| FY Dec 2025 | $11.9M |
| FY Dec 2024 | $1.3M |
| FY Dec 2023 | $19.1M |
| FY Dec 2022 | $4.8M |
| FY Dec 2021 | $2.8M |
| Jun 2026 | $7.4M |
| Mar 2026 | $1.4M |
| Dec 2025 | $9.7M |
| Sep 2025 | $10.7M |
| Jun 2025 | $4.1M |
| Mar 2025 | -$12.6M |
| Dec 2024 | $3.2M |
| Sep 2024 | $1.7M |
At each fiscal year end
Single quarter
Debt to equity
0.05x
long-term 2026-06-30 plus current 2026-06-30; equity 2026-06-30
Debt to equity VMD
| FY Dec 2025 | 0.09x |
| FY Dec 2024 | 0.03x |
| FY Dec 2023 | 0.06x |
| FY Dec 2022 | 0.00x |
| FY Dec 2021 | 0.06x |
| Jun 2026 | 0.05x |
| Mar 2026 | 0.06x |
| Dec 2025 | 0.09x |
| Sep 2025 | 0.16x |
| Jun 2025 | 0.03x |
| Mar 2025 | 0.03x |
| Dec 2024 | 0.03x |
| Sep 2024 | 0.04x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
8.57x
TTM operating cash flow over long-term 2026-06-30 plus current 2026-06-30
Cash flow to debt VMD
| FY Dec 2025 | 4.19x |
| FY Dec 2024 | 9.78x |
| FY Dec 2023 | 6.39x |
| FY Dec 2022 | n/a |
| FY Dec 2021 | 3.89x |
| Jun 2026 | 8.57x |
| Mar 2026 | 6.21x |
| Dec 2025 | 4.19x |
| Sep 2025 | 2.29x |
| Jun 2025 | 10.00x |
| Mar 2025 | 10.40x |
| Dec 2024 | 9.78x |
| Sep 2024 | 8.38x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
+10.5%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity VMD
| FY Dec 2025 | +11.3% |
| FY Dec 2024 | +9.3% |
| FY Dec 2023 | +9.7% |
| FY Dec 2022 | +6.5% |
| FY Dec 2021 | +10.3% |
| Jun 2026 | +10.5% |
| Mar 2026 | +11.0% |
| Dec 2025 | +11.3% |
| Sep 2025 | +10.6% |
| Jun 2025 | +10.9% |
| Mar 2025 | +9.9% |
| Dec 2024 | +9.3% |
| Sep 2024 | +8.9% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
+7.7%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets VMD
| FY Dec 2025 | +8.2% |
| FY Dec 2024 | +6.9% |
| FY Dec 2023 | +7.5% |
| FY Dec 2022 | +5.3% |
| FY Dec 2021 | +7.9% |
| Jun 2026 | +7.7% |
| Mar 2026 | +8.2% |
| Dec 2025 | +8.2% |
| Sep 2025 | +7.4% |
| Jun 2025 | +8.1% |
| Mar 2025 | +7.5% |
| Dec 2024 | +6.9% |
| Sep 2024 | +6.5% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
+12.1%
operating income after a 29.1% effective tax rate, over long-term 2026-06-30 plus current 2026-06-30 plus average of 2025-06-30 and 2026-06-30 minus cash
Return on invested capital VMD
| FY Dec 2025 | +12.2% |
| FY Dec 2024 | +11.3% |
| FY Dec 2023 | +10.4% |
| FY Dec 2022 | +7.8% |
| FY Dec 2021 | +13.1% |
| Jun 2026 | +12.1% |
| Mar 2026 | +11.8% |
| Dec 2025 | +12.2% |
| Sep 2025 | +10.5% |
| Jun 2025 | +12.3% |
| Mar 2025 | +11.4% |
| Dec 2024 | +11.3% |
| Sep 2024 | +10.6% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
+15.0%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed VMD
| FY Dec 2025 | +15.4% |
| FY Dec 2024 | +13.6% |
| FY Dec 2023 | +13.0% |
| FY Dec 2022 | +8.3% |
| FY Dec 2021 | +12.2% |
| Jun 2026 | +15.0% |
| Mar 2026 | +15.6% |
| Dec 2025 | +15.4% |
| Sep 2025 | +14.4% |
| Jun 2025 | +15.0% |
| Mar 2025 | +14.6% |
| Dec 2024 | +13.6% |
| Sep 2024 | +13.3% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
26.89x
close 2026-10-27 over four quarters of diluted EPS, 2025-07-01 to 2026-06-30
P/E, trailing VMD
| FY Dec 2025 | 20.08x |
| FY Dec 2024 | 27.66x |
| FY Dec 2023 | 31.40x |
| FY Dec 2022 | 47.25x |
| FY Dec 2021 | 23.73x |
| Jun 2026 | 31.67x |
| Mar 2026 | 24.89x |
| Dec 2025 | 20.08x |
| Sep 2025 | 19.97x |
| Jun 2025 | 19.74x |
| Mar 2025 | 23.48x |
| Dec 2024 | 27.66x |
| Sep 2024 | 28.19x |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$365.1M
market value at close 2026-10-27 on 2026-07-27 shares, plus long-term 2026-06-30 plus current 2026-06-30, minus cash 2026-06-30
Enterprise value VMD
| FY Dec 2025 | $281.4M |
| FY Dec 2024 | $298.7M |
| FY Dec 2023 | $296.4M |
| FY Dec 2022 | $270.5M |
| FY Dec 2021 | $184.2M |
| Jun 2026 | $433.5M |
| Mar 2026 | $355.0M |
| Dec 2025 | $281.4M |
| Sep 2025 | $273.4M |
| Jun 2025 | $257.4M |
| Mar 2025 | $281.5M |
| Dec 2024 | $298.7M |
| Sep 2024 | $277.7M |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
+7.9%
TTM free cash flow over market value at close 2026-10-27
FCF yield VMD
| FY Dec 2025 | +4.2% |
| FY Dec 2024 | +0.4% |
| FY Dec 2023 | +6.3% |
| FY Dec 2022 | +1.7% |
| FY Dec 2021 | +1.3% |
| Jun 2026 | +6.7% |
| Mar 2026 | +7.3% |
| Dec 2025 | +4.2% |
| Sep 2025 | +2.0% |
| Jun 2025 | -1.3% |
| Mar 2025 | -2.3% |
| Dec 2024 | +0.4% |
| Sep 2024 | +1.2% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
9.41x
P/E over trailing EPS growth of 3%: four quarters to 2026-06-30 against the four to 2025-06-30
PEG, trailing VMD
| FY Dec 2025 | 0.73x |
| FY Dec 2024 | 1.73x |
| FY Dec 2023 | 0.56x |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | 11.08x |
| Mar 2026 | 1.29x |
| Dec 2025 | 0.73x |
| Sep 2025 | 0.65x |
| Jun 2025 | 0.38x |
| Mar 2025 | 0.98x |
| Dec 2024 | 1.73x |
| Sep 2024 | 3.38x |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-27. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $270.3M | $224.3M | $183.0M | $138.8M |
| Gross profit | $155.5M | $133.2M | $112.8M | $84.7M |
| Operating income | $22.9M | $17.9M | $14.3M | $8.3M |
| Net income | $15.4M | $11.4M | $10.2M | $6.2M |
| EPS (diluted) | 0.37 | 0.28 | 0.25 | 0.16 |
| Operating cash flow | $51.9M | $39.1M | $45.2M | $27.7M |
| Cash | $13.5M | $17.5M | $12.8M | $16.9M |
| Long-term debt | $11.3M | $3.6M | $6.0M | $0 |
| Buybacks | $13.2M | $0 | $0 | $9.6M |
SEC XBRL, fiscal years, as known on 2026-10-28
VMD Stock Sonar score 6/7 axes
Find similar shapesCompareVMD ranks highest on financial health (88th percentile) and profitability (72nd), and lowest on insider conviction (31st), among Healthcare Services peers.
6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
VMD filings, in plain words
Are Viemed Healthcare insiders buying or selling VMD?
In the 180 days to 2026-10-28, Viemed Healthcare insiders were net sellers, a net $347.2K across purchases and sales reported on Form 4, by 2 sellers.
Read the full summary
In the 180 days to 2026-10-28, Viemed Healthcare insiders were net sellers of VMD, a net $347.2K across purchases and sales reported on Form 4 by 2 sellers. None of the 6 insider sales was flagged as made under a Rule 10b5-1 plan. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
